ReviewFrontiers in bioengineering and biotechnology2026
Integrated strategies in meniscus tissue engineering: from biomaterials to stem cell-driven regeneration.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Meniscal tissue engineering: Bridging clinical needs and experimental innovation.Journal of orthopaedic translation · 2026Review
- Embedded cell-only bioprinting to engineer structurally aligned meniscal fibrocartilage.Materials today. Bio · 2026Article
- Meniscus Tissue Engineering Scaffolds: Biomaterials, Biofabrication, and Translation.Polymers · 2026Review
- Self-assembled meniscus-specific ECM membrane promotes cell migration and vascular ingrowth for meniscus repair and reconstruction.Journal of orthopaedic translation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The meniscus is a fibrocartilaginous tissue essential for load distribution, shock absorption, and knee joint stability, yet its intrinsic healing potential is limited, particularly in the avascular inner zone. Conventional treatments such as partial meniscectomy, repair, or transplantation often fail to restore long-term biomechanical and biological function, underscoring the need for regenerative strategies. Meniscus tissue engineering (TE) has emerged as a promising approach that combines biomaterial scaffolds with stem cells to recreate the structural and functional complexity of the native tissue. This narrative review summarizes recent advances in scaffold design and cell-based therapies for meniscus repair. Natural materials such as collagen, alginate, and silk fibroin provide biocompatibility and bioactivity but lack sufficient mechanical strength, whereas synthetic polymers including PGA, PLA, PLGA, and polyurethane offer tunable degradation and structural reinforcement but are biologically inert. Composite scaffolds that integrate these material classes-through multiphase, gradient, or layered designs-represent a promising strategy to replicate zonal heterogeneity and anisotropic mechanics. On the cellular side, bone marrow-, adipose-, and synovium-derived mesenchymal stem cells have demonstrated potential for zone-specific regeneration, while induced pluripotent stem cells present opportunities for patient-specific therapies but remain limited by safety concerns. Advances in cell seeding strategies, including dynamic perfusion and 3D bioprinting, have further improved scaffold-cell integration. Finally, emerging technologies such as 3D/4D printing, smart responsive biomaterials, controlled drug delivery, dynamic bioreactors, and AI-assisted scaffold design provide new opportunities to overcome persistent challenges of vascularization, mechanical anisotropy, and clinical translation. While significant obstacles remain, the convergence of materials science, stem cell biology, advanced fabrication, and computational modeling offers a promising roadmap toward clinically viable meniscus regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.